OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
30
Results
Show all
Save search
Copy query
Show results for
Unknown
(30)
Publication Date
Release Date
2025
(7)
2023
(6)
2021
(3)
2020
(3)
2019
(3)
2026
(2)
2024
(2)
2018
(2)
2022
(1)
2012
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Not available
S-EPMC7948296
|
biostudies-literature
Cite
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.
Not available
S-EPMC10067047
|
biostudies-literature
Cite
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.
Not available
S-EPMC11310768
|
biostudies-literature
Cite
Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera<sup>®</sup> in low-tumor-burden follicular lymphoma: the FLINTER study.
Not available
S-EPMC12104602
|
biostudies-literature
Cite
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Not available
S-EPMC9807478
|
biostudies-literature
Cite
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Not available
S-EPMC8078325
|
biostudies-literature
Cite
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data.
Not available
S-EPMC11868350
|
biostudies-literature
Cite
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.
Not available
S-EPMC12789008
|
biostudies-literature
Cite
P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
Not available
S-EPMC10431001
|
biostudies-literature
Cite
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Not available
S-EPMC10651865
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets